Single oral dose escalation pharmacokinetics of pleconaril (VP 63843) capsules in adults

Pleconaril is an orally active broad-spectrum antipicornaviral agent with excellent penetration into the central nervous system and nasal epithelium. The authors report the results of a randomized, placebo-controlled, dose escalation study of pleconaril oral capsules following single-dose administration of 50 to 1000 mg. Fifty-six healthy adults (ages 19-55) participated in the study. Each subject received a single dose of pleconaril oral capsule(s) or an identically matched placebo. Blood samples (n = 19) were obtained over 36 hours postdose, and pleconaril was quantified from plasma by gas chromatography. Pleconaril disposition was best characterized using a two-compartment open-model with first-order absorption. Fifty-five subjects completed the study (31 +/- 10 years, 77.6 +/- 11 kg). The administration of pleconaril was well tolerated. There was no difference in tmax, lambda z, ka, t1/2elim, Cl/F, or Vdss/F among the various dose groups. A significant difference in both Cmax and AUC was observed between study groups; however, this difference became insignificant when the parameters were corrected for dose. Cmax and AUC were dose proportional between 50 and 1000 mg (r2 > 0.97 and 0.90, respectively). Pleconaril demonstrates a favorable safety and pharmacokinetic profile following single-dose administration.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. D. Ma, A. N. Nafziger, G. Rhodes, S. Liu, and J. S. Bertino Jr. DURATION OF PLECONARIL EFFECT ON CYTOCHROME P450 3A ACTIVITY IN HEALTHY ADULTS USING THE ORAL BIOMARKER MIDAZOLAM Drug Metab. Dispos., May 1, 2006; 34(5): 783 - 785. [Abstract] [Full Text] [PDF]

				J. D. Ma, A. N. Nafziger, G. Rhodes, S. Liu, A. M. Gartung, and J. S. Bertino Jr The Effect of Oral Pleconaril on Hepatic Cytochrome P450 3A Activity in Healthy Adults Using Intravenous Midazolam as a Probe J. Clin. Pharmacol., January 1, 2006; 46(1): 103 - 108. [Abstract] [Full Text] [PDF]

				C. Buoen, O. J. Bjerrum, and M. S. Thomsen How First-Time-in-Human Studies Are Being Performed: A Survey of Phase I Dose-Escalation Trials in Healthy Volunteers Published Between 1995 and 2004 J. Clin. Pharmacol., October 1, 2005; 45(10): 1123 - 1136. [Abstract] [Full Text] [PDF]

				D. C. Pevear, T. M. Tull, M. E. Seipel, and J. M. Groarke Activity of Pleconaril against Enteroviruses Antimicrob. Agents Chemother., September 1, 1999; 43(9): 2109 - 2115. [Abstract] [Full Text]